Cargando…

Cyclic AMP Accumulation in Migraine Induction

Investigators from Danish Headache Centre, Glostrup Hospital, and the University of Copenhagen investigated whether intracellular cyclic AMP accumulation induced migraine attacks among 14 migraine patients without aura.

Detalles Bibliográficos
Autores principales:	Chelse, Ana B., Epstein, Leon G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pediatric Neurology Briefs Publishers 2015
Materias:	Headache Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747305/ https://www.ncbi.nlm.nih.gov/pubmed/26933530 http://dx.doi.org/10.15844/pedneurbriefs-29-1-6

Ejemplares similares

Intracranial Hypertension in Children without Papilledema
por: Chelse, Ana B., et al.
Publicado: (2015)

Blunt Head Trauma and Headache
por: Chelse, Ana B., et al.
Publicado: (2015)

Acute Treatment Regimens for Migraine in the ED
por: Millichap, J. Gordon
Publicado: (2015)

Review of Prevention for Pediatric and Adolescent Migraine
por: Qubty, William, et al.
Publicado: (2016)

Migraine, Celiac Disease and Intestinal Microbiota
por: Rahmoune, Hakim, et al.
Publicado: (2017)

Vestibular migraine
por: Silva, Viviane Passarelli Ramin, et al.
Publicado: (2022)

Chronic migraine: Genetics or environment?
por: Chalmer, Mona Ameri, et al.
Publicado: (2021)

Cold extremities in migraine: a marker for vascular dysfunction in women
por: Linstra, K. M., et al.
Publicado: (2020)

Acute Migraine Therapy: New Drugs and New Approaches
por: Monteith, Teshamae S., et al.
Publicado: (2010)

Pediatric Intracranial Hypertension
por: Sivaswamy, Lalitha
Publicado: (2016)

Functional connectivity changes in complex migraine aura: beyond the visual network
por: Silvestro, Marcello, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Multinational descriptive analysis of the real‐world burden of headache using the Migraine Buddy application
por: Goadsby, Peter J., et al.
Publicado: (2021)

Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Autoimmune Post-Herpes Simplex Encephalitis
por: Chelse, Ana B., et al.
Publicado: (2016)

Basic Considerations for the Use of Monoclonal Antibodies in Migraine
por: Levin, Morris, et al.
Publicado: (2018)

Habituation of single CO(2) laser–evoked responses during interictal phase of migraine
por: de Tommaso, M., et al.
Publicado: (2005)

Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study
por: Grosberg, Brian, et al.
Publicado: (2021)

Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature
por: Fernández‐de‐las‐Peñas, César, et al.
Publicado: (2021)

Headaches and obesity
por: Fortini, Ida, et al.
Publicado: (2022)

Update on Idiopathic Intracranial Hypertension Management
por: Souza, Marcio Nattan Portes, et al.
Publicado: (2022)

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
por: de Vries Lentsch, Simone, et al.
Publicado: (2021)

First‐line steroid treatment for spontaneous intracranial hypotension
por: Tonello, Simone, et al.
Publicado: (2022)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Behavioural intervention in medication overuse headache: A concealed double‐blind randomized controlled trial
por: Pijpers, Judith A., et al.
Publicado: (2022)

Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials
por: Hindiyeh, Nada A., et al.
Publicado: (2019)

Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review
por: Klein, Antonia, et al.
Publicado: (2021)

Migraine in the emergency department: a psychometric study of a migraine “repeaters” sample
por: Villani, V., et al.
Publicado: (2005)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Preventing chronicity of migraine
por: Fanciullacci, M., et al.
Publicado: (2005)

The History of the Migraine Trust
por: Rose, F. C.
Publicado: (2006)

The Temperament and Character Inventory in women with migraine
por: Mongini, F., et al.
Publicado: (2005)

Structural Connectivity in Gilles de la Tourette Syndrome
por: Chelse, Ana B., et al.
Publicado: (2015)

Atypical Perfusion Manifestation in Migraine with Aura
por: Lester, Jacobo, et al.
Publicado: (2021)

Prevalence of patent foramen ovale in a large series of patients with migraine with aura, migraine without aura and cluster headache, and relationship with clinical phenotype
por: Dalla Volta, G., et al.
Publicado: (2005)

Preventive non–pharmacological treatment and nitric oxide in chronic migraine
por: Ciancarelli, I., et al.
Publicado: (2005)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_up3pd25s2nepbap3jjemhvost6